Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

INBXBullishIndustry Newsnews

High materiality9/10

Inhibrx's INBRX-106 shows strong HPV+ responses; accelerated path possible

Sep 8, 2026, 7:36 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong efficacy signals in a randomized setting, especially in HPV+ patients, plus an accelerated pathway potential and Phase 3 advancement could drive a re-rating of INBX on upside scenarios; risk remains until confirmatory Phase 3 data and regulatory positioning.

AI summary

What happened, with direct paths to the underlying reporting

Inhibrx reported Phase 2 HexAgon results for INBRX-106 plus pembrolizumab in first-line HNSCC, with cORR 48.3% and 6-month PFS 72.4% versus pembrolizumab alone. HPV+ patients driven outperformance (80% cORR, 30% CR, 90% PFS6). The company plans a ~50-patient HPV+ OPSCC expansion to pursue accelerated regulatory pathways and will advance to Phase 3, while a NSCLC perioperative readout is due mid-2027.

INBRX-106 + pembrolizumab: cORR 48.3%, 6-month PFS 72.4%.
HPV+ cohort: cORR 80%, CR 30%, PFS6 90%.
Phase 2 expansion planned for ~50 HPV+ OPSCC patients for accelerated pathway.
Phase 3 planned after expansion; broader immunogenic tumor exploration ongoing.
NSCLC perioperative trial readout targeted for mid-2027.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Inhibrx's INBRX-106 shows strong HPV+ responses; accelerated path possible

Inhibrx mid-stage head/neck data could act as near-term INBX catalyst

Inhibrx Reports Strong Interim Phase 2 Data for INBX-106 Therapy

Inhibrx Attracts Major Interest for $8 Billion Cancer Treatment

Why Inhibrx's Recent Strength May Not Be Built to Last